Tempest Therapeutics, Inc. announced the completion of an all-stock transaction to acquire dual-targeting CAR-T assets, including TPST-2003, with a BLA filing planned for China in 2027. The company’s operational runway is extended to mid-2027, with new President and CEO, Dr. Matt Angel, leading the way. The board is optimistic about the financial stability and potential milestones that lie ahead. The company plans to develop a diverse pipeline of potential therapies for various cancers, including liver cancer and multiple myeloma. Advisors like MTS Health Partners and Cooley LLP played key roles in the transaction. Tempest is focused on bringing innovative therapies to patients.

Read more at GlobeNewswire.: Tempest Announces Closing of Strategic Acquisition of